Sex differences in prevalence of drug therapy in Sweden in 2010 by pharmacological group
| ATC | Pharmacological group | PAT/TIN | RR (95% CI) | Age-adjusted RR (95% CI) | |
|---|---|---|---|---|---|
| Men | Women | Women/men | Women/men | ||
| J02 | Antimycotics for systemic use | 2.75 | 18.90 | 6.87 (6.74 to 7.00) | 6.56 (6.44 to 6.68) |
| M05 | Drugs for treatment of bone diseases | 3.19 | 19.28 | 6.04 (5.94 to 6.14) | 4.95 (4.87 to 5.03) |
| H03 | Thyroid therapy | 13.12 | 65.67 | 5.00 (4.96 to 5.05) | 4.46 (4.42 to 4.50) |
| N02C | Antimigraine Preparations | 5.03 | 17.24 | 3.43 (3.38 to 3.48) | 3.44 (3.39 to 3.49) |
| A12 | Mineral supplements | 16.19 | 57.29 | 3.54 (3.51 to 3.57) | 2.90 (2.88 to 2.92) |
| A08 | Antiobesity preparations | 1.59 | 4.13 | 2.60 (2.53 to 2.67) | 2.62 (2.55 to 2.69) |
| J05 | Antivirals for systemic use | 7.85 | 14.79 | 1.88 (1.86 to 1.91) | 1.86 (1.84 to 1.89) |
| P01 | Antiprotozoals | 11.00 | 20.55 | 1.87 (1.85 to 1.89) | 1.85 (1.83 to 1.87) |
| N06A | Antidepressants | 55.35 | 106.60 | 1.93 (1.92 to 1.93) | 1.79 (1.78 to 1.80) |
| H01 | Pituitary and hypothalamic hormones and analogues | 2.46 | 4.08 | 1.66 (1.62 to 1.70) | 1.66 (1.63 to 1.70) |
| N05B | Anxiolytics | 39.39 | 70.01 | 1.78 (1.77 to 1.79) | 1.60 (1.59 to 1.61) |
| N05C | Hypnotics and sedatives | 58.35 | 103.83 | 1.78 (1.77 to 1.79) | 1.56 (1.56 to 1.57) |
| M03 | Muscle relaxants | 6.38 | 9.98 | 1.56 (1.54 to 1.59) | 1.53 (1.51 to 1.56) |
| B03 | Antianaemic preparations | 40.35 | 73.24 | 1.82 (1.81 to 1.83) | 1.48 (1.47 to 1.49) |
| J01 | Antibacterials for systemic use | 191.26 | 265.58 | 1.39 (1.39 to 1.39) | 1.36 (1.36 to 1.36) |
| L04 | Immunosuppressants | 7.32 | 10.05 | 1.37 (1.35 to 1.39) | 1.33 (1.31 to 1.35) |
| G04BD | Urinary antispasmodics | 6.12 | 9.61 | 1.57 (1.55 to 1.60) | 1.33 (1.31 to 1.35) |
| A02 | Drugs for acid related disorders | 70.08 | 101.87 | 1.45 (1.45 to 1.46) | 1.31 (1.31 to 1.32) |
| H02 | Corticosteroids for systemic use | 37.17 | 51.98 | 1.40 (1.39 to 1.41) | 1.30 (1.30 to 1.31) |
| S01B | Anti-inflammatory agents | 12.72 | 18.95 | 1.49 (1.47 to 1.50) | 1.30 (1.29 to 1.31) |
| A07 | Antidiarrhoeals, intestinal anti-inflammatory/anti-infective agents | 13.77 | 19.35 | 1.40 (1.39 to 1.42) | 1.29 (1.28 to 1.30) |
| N02A | Opioids | 66.90 | 92.97 | 1.39 (1.38 to 1.40) | 1.27 (1.27 to 1.28) |
| C03 | Diuretics | 59.48 | 92.83 | 1.56 (1.55 to 1.57) | 1.24 (1.24 to 1.25) |
| S02 | Otologicals | 4.54 | 5.71 | 1.26 (1.24 to 1.28) | 1.23 (1.21 to 1.25) |
| R03 | Drugs for obstructive airway diseases | 71.79 | 88.80 | 1.24 (1.23 to 1.24) | 1.20 (1.20 to 1.21) |
| S03 | Ophthalmological and otological preparations | 23.31 | 28.38 | 1.22 (1.21 to 1.23) | 1.18 (1.17 to 1.19) |
| N03 | Antiepileptics | 18.22 | 22.08 | 1.21 (1.20 to 1.22) | 1.15 (1.14 to 1.16) |
| N05A | Antipsychotics | 13.59 | 16.51 | 1.21 (1.20 to 1.23) | 1.11 (1.09 to 1.12) |
| N06D | Antidementia drugs | 3.38 | 5.41 | 1.60 (1.57 to 1.63) | 1.10 (1.07 to 1.12) |
| N04 | Anti-Parkinson drugs | 6.83 | 8.49 | 1.24 (1.22 to 1.26) | 1.06 (1.05 to 1.08) |
| S01E | Antiglaucoma preparations and miotics | 13.57 | 18.49 | 1.36 (1.35 to 1.38) | 1.02 (1.01 to 1.03) |
| L02 | Endocrine therapy | 6.34 | 7.60 | 1.20 (1.18 to 1.22) | 0.96 (0.95 to 0.97) |
| C07 | β blocking agents | 97.82 | 107.57 | 1.10 (1.10 to 1.10) | 0.94 (0.93 to 0.94) |
| C09C+D | Angiotensin II antagonists and combinations | 45.16 | 46.56 | 1.03 (1.02 to 1.04) | 0.91 (0.91 to 0.92) |
| C08 | Calcium channel blockers | 60.84 | 59.61 | 0.98 (0.97 to 0.98) | 0.84 (0.84 to 0.84) |
| C01A | Cardiac glycosides | 6.01 | 6.83 | 1.14 (1.12 to 1.16) | 0.81 (0.79 to 0.82) |
| C10 | Lipid modifying agents | 98.03 | 81.05 | 0.83 (0.82 to 0.83) | 0.74 (0.73 to 0.74) |
| C01D | Vasodilators used in cardiac diseases | 24.94 | 23.61 | 0.95 (0.94 to 0.95) | 0.73 (0.72 to 0.73) |
| B01 | Antithrombotic agents | 109.81 | 97.68 | 0.89 (0.89 to 0.89) | 0.72 (0.72 to 0.73) |
| A10 | Drugs used in diabetes | 45.27 | 34.48 | 0.76 (0.76 to 0.77) | 0.68 (0.68 to 0.69) |
| C09A+B | ACE-inhibitors and combinations | 78.14 | 60.90 | 0.78 (0.78 to 0.78) | 0.68 (0.67 to 0.68) |
| N06B | Psychostimulants | 6.94 | 4.11 | 0.59 (0.58 to 0.60) | 0.62 (0.61 to 0.64) |
| M04 | Antigout preparations | 12.24 | 5.91 | 0.48 (0.48 to 0.49) | 0.38 (0.38 to 0.39) |
Crude and age-adjusted relative differences for included ATC groups. The following pharmacological groups are not presented in the table due to sex-specific indications; G02 Other gynaecologicals (dispensed to 9.79 PAT/1000 women and 0.20 PAT/1000 men), G03A Hormonal contraceptives (dispensed to 132.05 PAT/1000 women and 0.08 PAT/1000 men), G03C Estrogens (dispensed to 69.62 PAT/1000 women and 0.08 PAT/1000 men), G03D Progestogens (dispensed to 15.90 PAT/1000 women and 0.03 PAT/1000 men), G03F Progestogens and Estrogens in combination (dispensed to 12.26 PAT/1000 women and 0.00 PAT/1000 men), G04C Drugs used in benign prostatic hypertrophy (dispensed to 0.25 PAT/1000 women and 26.23 PAT/1000 men) and G04BE Drugs used in erectile dysfunction (dispensed to 25.38 PAT/1000 men and 0.07 PAT/1000 women).
The relative differences were calculated with women as the numerator and men as the denominator. The table is sorted starting with the group with the largest age-adjusted sex difference. PAT/TIN=number of patients (men or women) per 1000 individuals. N=4 649 014 men and 4 691 668 women.
ATC, Anatomical Therapeutic Chemical; RR, risk ratio.